Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Allergy immunotherapy Market

ID: MRFR/HC/0988-CR
200 Pages
Nidhi Mandole
Last Updated: April 24, 2026

Allergy Immunotherapy Market Research Report: Size, Share, Trend Analysis By Types (Subcutaneous Immunotherapy, Sublingual Immunotherapy, Oral Immunotherapy), By Product (Allergen Extracts, Conventional Immunotherapy, Biologics), By Indication (Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, Food Allergies), By Patient Type (Pediatric, Adult, Geriatric) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Allergy immunotherapy Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Type (USD Billion) | |
      1. 4.1.1 Subcutaneous Immunotherapy | |
      2. 4.1.2 Sublingual Immunotherapy | |
      3. 4.1.3 Oral Immunotherapy |
    2. 4.2 Healthcare, BY Product (USD Billion) | |
      1. 4.2.1 Allergen Extracts | |
      2. 4.2.2 Conventional Immunotherapy | |
      3. 4.2.3 Biologics |
    3. 4.3 Healthcare, BY Indication (USD Billion) | |
      1. 4.3.1 Allergic Rhinitis | |
      2. 4.3.2 Allergic Asthma | |
      3. 4.3.3 Atopic Dermatitis | |
      4. 4.3.4 Food Allergies |
    4. 4.4 Healthcare, BY Patient Type (USD Billion) | |
      1. 4.4.1 Pediatric | |
      2. 4.4.2 Adult | |
      3. 4.4.3 Geriatric |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Allergopharma (DE) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Anergis (CH) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 ALK-Abello (DK) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Merck Group (DE) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Stallergenes Greer (GB) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 HollisterStier Allergy (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Circassia Pharmaceuticals (GB) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 DBV Technologies (FR) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Rho (US) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY TYPE |
    7. 6.4 US MARKET ANALYSIS BY PRODUCT |
    8. 6.5 US MARKET ANALYSIS BY INDICATION |
    9. 6.6 US MARKET ANALYSIS BY PATIENT TYPE |
    10. 6.7 CANADA MARKET ANALYSIS BY TYPE |
    11. 6.8 CANADA MARKET ANALYSIS BY PRODUCT |
    12. 6.9 CANADA MARKET ANALYSIS BY INDICATION |
    13. 6.10 CANADA MARKET ANALYSIS BY PATIENT TYPE |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY TYPE |
    16. 6.13 GERMANY MARKET ANALYSIS BY PRODUCT |
    17. 6.14 GERMANY MARKET ANALYSIS BY INDICATION |
    18. 6.15 GERMANY MARKET ANALYSIS BY PATIENT TYPE |
    19. 6.16 UK MARKET ANALYSIS BY TYPE |
    20. 6.17 UK MARKET ANALYSIS BY PRODUCT |
    21. 6.18 UK MARKET ANALYSIS BY INDICATION |
    22. 6.19 UK MARKET ANALYSIS BY PATIENT TYPE |
    23. 6.20 FRANCE MARKET ANALYSIS BY TYPE |
    24. 6.21 FRANCE MARKET ANALYSIS BY PRODUCT |
    25. 6.22 FRANCE MARKET ANALYSIS BY INDICATION |
    26. 6.23 FRANCE MARKET ANALYSIS BY PATIENT TYPE |
    27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE |
    28. 6.25 RUSSIA MARKET ANALYSIS BY PRODUCT |
    29. 6.26 RUSSIA MARKET ANALYSIS BY INDICATION |
    30. 6.27 RUSSIA MARKET ANALYSIS BY PATIENT TYPE |
    31. 6.28 ITALY MARKET ANALYSIS BY TYPE |
    32. 6.29 ITALY MARKET ANALYSIS BY PRODUCT |
    33. 6.30 ITALY MARKET ANALYSIS BY INDICATION |
    34. 6.31 ITALY MARKET ANALYSIS BY PATIENT TYPE |
    35. 6.32 SPAIN MARKET ANALYSIS BY TYPE |
    36. 6.33 SPAIN MARKET ANALYSIS BY PRODUCT |
    37. 6.34 SPAIN MARKET ANALYSIS BY INDICATION |
    38. 6.35 SPAIN MARKET ANALYSIS BY PATIENT TYPE |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY PRODUCT |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY INDICATION |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY PATIENT TYPE |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY TYPE |
    45. 6.42 CHINA MARKET ANALYSIS BY PRODUCT |
    46. 6.43 CHINA MARKET ANALYSIS BY INDICATION |
    47. 6.44 CHINA MARKET ANALYSIS BY PATIENT TYPE |
    48. 6.45 INDIA MARKET ANALYSIS BY TYPE |
    49. 6.46 INDIA MARKET ANALYSIS BY PRODUCT |
    50. 6.47 INDIA MARKET ANALYSIS BY INDICATION |
    51. 6.48 INDIA MARKET ANALYSIS BY PATIENT TYPE |
    52. 6.49 JAPAN MARKET ANALYSIS BY TYPE |
    53. 6.50 JAPAN MARKET ANALYSIS BY PRODUCT |
    54. 6.51 JAPAN MARKET ANALYSIS BY INDICATION |
    55. 6.52 JAPAN MARKET ANALYSIS BY PATIENT TYPE |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY PRODUCT |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY INDICATION |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY PATIENT TYPE |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY PRODUCT |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY INDICATION |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY PATIENT TYPE |
    64. 6.61 THAILAND MARKET ANALYSIS BY TYPE |
    65. 6.62 THAILAND MARKET ANALYSIS BY PRODUCT |
    66. 6.63 THAILAND MARKET ANALYSIS BY INDICATION |
    67. 6.64 THAILAND MARKET ANALYSIS BY PATIENT TYPE |
    68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE |
    69. 6.66 INDONESIA MARKET ANALYSIS BY PRODUCT |
    70. 6.67 INDONESIA MARKET ANALYSIS BY INDICATION |
    71. 6.68 INDONESIA MARKET ANALYSIS BY PATIENT TYPE |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY PRODUCT |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY INDICATION |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY PATIENT TYPE |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE |
    78. 6.75 BRAZIL MARKET ANALYSIS BY PRODUCT |
    79. 6.76 BRAZIL MARKET ANALYSIS BY INDICATION |
    80. 6.77 BRAZIL MARKET ANALYSIS BY PATIENT TYPE |
    81. 6.78 MEXICO MARKET ANALYSIS BY TYPE |
    82. 6.79 MEXICO MARKET ANALYSIS BY PRODUCT |
    83. 6.80 MEXICO MARKET ANALYSIS BY INDICATION |
    84. 6.81 MEXICO MARKET ANALYSIS BY PATIENT TYPE |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY PRODUCT |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY INDICATION |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY PATIENT TYPE |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRODUCT |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT TYPE |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY PRODUCT |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY INDICATION |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY PATIENT TYPE |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY PRODUCT |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY INDICATION |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY PATIENT TYPE |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY PRODUCT |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY INDICATION |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY PATIENT TYPE |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY PRODUCT, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY PRODUCT, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY INDICATION, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY PATIENT TYPE, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY PATIENT TYPE, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY PRODUCT, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

  • Subcutaneous Immunotherapy
  • Sublingual Immunotherapy
  • Oral Immunotherapy

Healthcare By Product (USD Billion, 2025-2035)

  • Allergen Extracts
  • Conventional Immunotherapy
  • Biologics

Healthcare By Indication (USD Billion, 2025-2035)

  • Allergic Rhinitis
  • Allergic Asthma
  • Atopic Dermatitis
  • Food Allergies

Healthcare By Patient Type (USD Billion, 2025-2035)

  • Pediatric
  • Adult
  • Geriatric

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions